Last reviewed · How we verify
Brimonidine tartrate ophthalmic solution 0.025% — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Brimonidine tartrate ophthalmic solution 0.025% (Brimonidine tartrate ophthalmic solution 0.025%) — Bausch & Lomb Incorporated.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Brimonidine tartrate ophthalmic solution 0.025% TARGET | Brimonidine tartrate ophthalmic solution 0.025% | Bausch & Lomb Incorporated | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Brimonidine tartrate ophthalmic solution 0.025% CI watch — RSS
- Brimonidine tartrate ophthalmic solution 0.025% CI watch — Atom
- Brimonidine tartrate ophthalmic solution 0.025% CI watch — JSON
- Brimonidine tartrate ophthalmic solution 0.025% alone — RSS
Cite this brief
Drug Landscape (2026). Brimonidine tartrate ophthalmic solution 0.025% — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-tartrate-ophthalmic-solution-0-025. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab